IRVINE, Calif., June 10, 2005 (PRIMEZONE) -- "Limitations on domestic stem cell research may have an impact on major biopharmaceutical companies as well," stated SmallCap Sentinel analyst, D.R. Clark. "It will be interesting to see if the proposed restrictions of stem cell research in the United States eventually impact large pharmaceutical firms, either positively or adversely."
"In the highly competitive biopharmaceutical and pharmaceutical markets, acquisition of new drugs and technologies based on all kinds of research and development is imperative," Clark added. "Should restrictions specific to U.S. soil inhibit research here it would seem that companies desirous of new products would pursue technology developed abroad. Industry leaders such as Genentech, Inc. (NYSE:DNA), Sepracor Inc. (Nasdaq:SEPR), and Celgene Corporation (Nasdaq:CELG) must be pondering this politically-charged circumstance."
"Meanwhile, stem cell related companies like New Life Scientific (OTCBB:NWLF) have added foreign-based research divisions to their business models," added Clark.
An informational report regarding New Life Scientific has been made available to the public free of charge at:
http://www.stockupticks.com/news_images/NWLF1.pdf
Individuals may also register free of charge for future reports at the following link:
http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice or research. MP has been paid been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.